Miguel Forte | CEO, Kiji Therapeutics and President, International Society of Cell and Gene Therapy
Kiji Therapeutics

Immediate Past President and Board of Directors member of the International Society of Cell and Gene Therapy (ISCT) from June 2026. Previously President ISCT 2024 to 2026. Chief Commercialization Officer and Chair of the ISCT Commercialization Committee (2014-2020). CEO and Co-Founder of Kiji Therapeutics, Executive Chairman of Akatsuki Therapeutics, member of the Board of StemBond, Swarm Oncology and Blue Cells, consulting through mC4Tx, Professor at the Lisbon University and Board of Directors and Executive Committee member for Alliance for Regenerative Medicine (ARM). Previously CEO of Bone Therapeutics (2019-2022). CEO of Zelluna Immunotherapy (2017-2019). From 2010-2017 CMO/COO of TxCell. From 2006-2010 was VP of Global Medical Affairs at UCB. In 2004, joined Nabi Pharmaceuticals as the VP of Medical/Regulatory Affairs for Europe. After several public sector clinical, academic, and regulatory positions in Portugal and at the European Medicines Agency (EMA), namely as CHMP member, spent six years with BMS (1998-2003) as Country Medical Director, Executive Director, and VP of International Medical in Portugal and Belgium. Holds an M.D. and Specialist in Infectious Diseases from the Faculty of Medicine, University of Lisbon, a Ph.D. in Immunology, University of Birmingham, and a certificate on Health Technologies Economics, Stockholm School of Economics. He is Fellow of the Faculty of Pharmaceutical Medicine of the RCP in the UK.